LncRNA GAS5 Represses Osteosarcoma Cells Growth and Metastasis via Sponging MiR-203a

Background/Aims: LncRNA GAS5, a growth suppressor, has been reported to exert anti-tumor actions in various cancers, whereas the exact mechanism underling the anti-tumor action is still unclear. This study was aimed to investigate the effect of lncRNA GAS5 on osteosarcoma and tried to decode the underling mechanisms. Methods: Expressions of lncRNA GAS5 in MG-63 cells were silenced by shRNA transfection, while were overexpressed by vector transfection. Cell viability, migration, invasion and apoptosis were respectively assessed by MTT, Transwell assay and flow cytometry. Regulations between lncRNA GAS5 and miR-203a, as well as between miR-203a and TIMP2 were detected by qPCR, western blot and dual luciferase activity assay. Results: LncRNA GAS5 was down-regulated in MG-63 and OS-732 cells compared to hFOB1.19 cells. Silence of lncRNA GAS5 significantly promoted MG-63 cells viability, migration and invasion, and up-regulated Cyclin D1, Cyclin B1, CDK1 and CDK4 expressions. miR-203a was negatively regulated by lncRNA GAS5. The promoting activities of lncRNA GAS5 silence on MG-63 cells growth and metastasis were reversed by miR-203a suppression. TIMP2 was a target of miR-203a and the anti-growth and anti-metastasis actions of miR-203a suppression were reversed by TIMP2 silence. Further, lncRNA GAS5 silence, miR-203a overexpression, and TIMP2 silence could activate PI3K/AKT/GSK3β signaling while block NF-κB signaling. Conclusion: LncRNA GAS5 might be a tumor suppressor in osteosarcoma via sponging miR-203a, sequestering miR-203a away from TIMP2.

[1]  N. Lemoine,et al.  Adenoviral delivery of TIMP1 or TIMP2 can modify the invasive behavior of pancreatic cancer and can have a significant antitumor effect in vivo , 2001, Cancer Gene Therapy.

[2]  Thomas D. Schmittgen,et al.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.

[3]  Piero Picci,et al.  Prognostic factors for osteosarcoma of the extremity treated with neoadjuvant chemotherapy , 2006, Cancer.

[4]  P. Picci.  Osteosarcoma (Osteogenic sarcoma) , 2007, Orphanet journal of rare diseases.

[5]  G. Stoica,et al.  MMP2 role in breast cancer brain metastasis development and its regulation by TIMP2 and ERK1/2 , 2007, Clinical & Experimental Metastasis.

[6]  S. Shenouda,et al.  MicroRNA function in cancer: oncogene or a tumor suppressor? , 2009, Cancer and Metastasis Reviews.

[7]  Sonya S. Shin,et al.  Development of extensively drug-resistant tuberculosis during multidrug-resistant tuberculosis treatment. , 2010, American journal of respiratory and critical care medicine.

[8]  M. Mourtada-Maarabouni,et al.  Inhibition of Human T-Cell Proliferation by Mammalian Target of Rapamycin (mTOR) Antagonists Requires Noncoding RNA Growth-Arrest-Specific Transcript 5 (GAS5) , 2010, Molecular Pharmacology.

[9]  Guoku Hu,et al.  Binding of NF-kappaB p65 subunit to the promoter elements is involved in LPS-induced transactivation of miRNA genes in human biliary epithelial cells , 2010, Nucleic acids research.

[10]  Carolyn J. Brown,et al.  The functional role of long non-coding RNA in human carcinomas , 2011, Molecular Cancer.

[11]  D. Cacchiarelli,et al.  A Long Noncoding RNA Controls Muscle Differentiation by Functioning as a Competing Endogenous RNA , 2011, Cell.

[12]  J. Haddad,et al.  NF-κB cellular and molecular regulatory mechanisms and pathways: therapeutic pattern or pseudoregulation? , 2011, Cellular immunology.

[13]  M. Esteller.  Non-coding RNAs in human disease , 2011, Nature Reviews Genetics.

[14]  Howard Y. Chang,et al.  Genome regulation by long noncoding RNAs. , 2012, Annual review of biochemistry.

[15]  Wei Gao,et al.  Long non-coding RNA GAS5 functions as a tumor suppressor in renal cell carcinoma. , 2013, Asian Pacific journal of cancer prevention : APJCP.

[16]  K. Morris,et al.  Long antisense non-coding RNAs and the epigenetic regulation of gene expression , 2013, Biomolecular concepts.

[17]  C. Peng,et al.  Downregulation of gas5 increases pancreatic cancer cell proliferation by regulating CDK6 , 2013, Cell and Tissue Research.

[18]  Wei Zhao,et al.  Decreased expression of lncRNA GAS5 predicts a poor prognosis in cervical cancer. , 2014, International journal of clinical and experimental pathology.

[19]  G. Dorn,et al.  Menage a Trois: intimate relationship among a microRNA, long noncoding RNA, and mRNA. , 2014, Circulation research.

[20]  R. Kong,et al.  Long noncoding RNA GAS5 affects cell proliferation and predicts a poor prognosis in patients with colorectal cancer , 2014, Medical Oncology.

[21]  Gwyn T. Williams,et al.  Regulation of apoptosis by long non-coding RNA GAS5 in breast cancer cells: implications for chemotherapy , 2014, Breast Cancer Research and Treatment.

[22]  Xuefei Shi,et al.  A critical role for the long non‐coding RNA GAS5 in proliferation and apoptosis in non‐small‐cell lung cancer , 2015, Molecular carcinogenesis.

[23]  J. Zhao,et al.  lncRNA GAS5 enhances G1 cell cycle arrest via binding to YBX1 to regulate p21 expression in stomach cancer , 2015, Scientific Reports.

[24]  A. Abarrategi,et al.  Osteosarcoma: Cells-of-Origin, Cancer Stem Cells, and Targeted Therapies , 2016, Stem cells international.

[25]  Li-Na Jin,et al.  A tumor suppressive role of lncRNA GAS5 in human colorectal cancer , 2016 .

[26]  S. Batra,et al.  Transcription Factor NF-κB: An Update on Intervention Strategies , 2016, Archivum Immunologiae et Therapiae Experimentalis.

[27]  Xin-hua Liang,et al.  The crosstalk between lncRNA and microRNA in cancer metastasis: orchestrating the epithelial-mesenchymal plasticity , 2016, Oncotarget.

[28]  N. Leslie,et al.  GSK3 and its interactions with the PI3K/AKT/mTOR signalling network. , 2017, Advances in biological regulation.